Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
U2nbyK2E0erz9gTG
Listen
